Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Ascletis, Eisai, Eli Lilly, Elpiscience, Gilead Sciences, Immuron, Incyte, Kadmon, Moleculin, Resverlogix, Therapeutic Solutions International, Turning Point, Very, Yiling, Zai Lab.